Ireland· IE-PA-EU/1/15/1032/001
Zerbaxa 1 g/0.5 g powder for concentrate for solution for infusion
A ceftolozan und beta-lactamase-inhibitor product containing ceftolozane sulfate + tazobactam sodium, registered in Ireland by Merck Sharp & Dohme BV,. The same ATC class is registered in 11 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Ceftolozan und beta-lactamase-inhibitor is registered in 11 of 19 countries.
Countries holding a registration under ATC J01DI54 (ceftolozan und beta-lactamase-inhibitor), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 7 of them publish a price we can compare per daily dose
Ceftolozan und beta-lactamase-inhibitor · ATC J01DI54
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
HPRA (Ireland)- Active substance
- Ceftolozane sulfate + Tazobactam sodium
- Manufacturer
- Merck Sharp & Dohme BV,
- Country
- Ireland (IE)
- ATC code
- J01DI54
- ATC class
- Ceftolozan und Beta-Lactamase-Inhibitor
- Defined daily dose
- 3 g, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/15/1032/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ceftolozan und beta-lactamase-inhibitor in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaZERBAXAMERCK CANADA INC
- SwitzerlandZerbaxa 1.5 g, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungMSD Merck Sharp & Dohme AG
- CzechiaZERBAXAMerck Sharp & Dohme B.V., Haarlem
- SpainZERBAXA 1 G/0,5 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONMerck Sharp & Dohme B.V.
- FinlandZerbaxaMerck Sharp & Dohme B.V.
- FranceZERBAXA 1 g/0,5 g, poudre pour solution à diluer pour perfusionMERCK SHARP & DOHME (PAYS-BAS)
- United KingdomZerbaxa 1g/0.5g powder for concentrate for solution for infusion vialsMerck Sharp & Dohme (UK) Ltd
- IcelandZerbaxaMerck Sharp & Dohme B.V.*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zerbaxa
- Liechtenstein · Zerbaxa
- Norway · Zerbaxa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/db5199f5-58d6-423d-b7da-5a5fe2e5cd69 GET /v1/drugs/db5199f5-58d6-423d-b7da-5a5fe2e5cd69?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for concentrate for solution for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"J01DI",
"J01DI54"
],
"strength": null,
"pa_number": "EU/1/15/1032/001",
"substances": [
"Ceftolozane sulfate",
"Tazobactam sodium"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "18/09/2015",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about ceftolozan und beta-lactamase-inhibitor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.